At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 164 enrolled
Drug / intervention
RVL-1201 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis
In Brief
A Phase 3 clinical trial evaluating RVL-1201 and Vehicle ophthalmic solution for Blepharoptosis. Completed, enrolled 164 participants across 36 sites.
Detailed Summary
Phase 3 study to evaluate the safety and efficacy of treatment with RVL-1201 compared to placebo for treatment of blepharoptosis. Eligible subjects will be randomized to one of 2 treatment arms.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBlepharoptosis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedJun 2018
Enrollment StartJun 2018
Primary CompletionApr 2019
Study CompletionApr 2019
TodayJul 2026
First PostedJun 21, 2018
Enrollment StartJun 28, 2018
Primary CompletionApr 11, 2019
Study CompletionApr 22, 2019
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 8.0 years ago
Interventions
RVL-1201drug
RVL-1201 ophthalmic solution 0.1%
Vehicle ophthalmic solutionother
Vehicle placebo ophthalmic solution